4TX

5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid

Created:2015-05-27
Last modified:  2015-08-05

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count40
Chiral Atom Count0
Bond Count40
Aromatic Bond Count6
2D diagram of 4TX
Toggle HydrogenToggle Labels

Chemical Component Summary

Name5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
Systematic Name (OpenEye OEToolkits)5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
FormulaC15 H22 O3
Molecular Weight250.333
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01c1c(OCCCC(C(=O)O)(C)C)c(ccc1C)C
SMILESCACTVS3.385Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1
SMILESOpenEye OEToolkits1.9.2Cc1ccc(c(c1)OCCCC(C)(C)C(=O)O)C
Canonical SMILESCACTVS3.385 Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1
Canonical SMILESOpenEye OEToolkits1.9.2 Cc1ccc(c(c1)OCCCC(C)(C)C(=O)O)C
InChIInChI1.03 InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
InChIKeyInChI1.03 HEMJJKBWTPKOJG-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB01241 
NameGemfibrozil
Groups
  • approved
  • investigational
DescriptionGemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Synonyms
  • Gemfibrozilo
  • Gemfibrozilum
  • 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure
  • 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid
  • Gemfibrozil
Brand Names
  • Gemfibrozil Cap 300mg
  • Apo-gemfibrozil
  • Gemfibrozil
  • Gemfibrozil-600 - Tab 600mg
  • Teva-gemfibrozil
IndicationGemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Categories
  • Acids, Acyclic
  • Agents Causing Muscle Toxicity
  • Benzene Derivatives
  • Butyrates
  • Chemically-Induced Disorders
ATC-CodeC10AB04
CAS number25812-30-0

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Peroxisome proliferator-activated receptor alphaMVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFG...unknownagonist
Lipoprotein lipaseMESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTPEDTA...unknownactivator
Solute carrier organic anion transporter family member 1B1MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKS...unknowninhibitor
Organic anion transporter 3MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...unknowninhibitor
Solute carrier organic anion transporter family member 2B1MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKL...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL457
PubChem 3463
ChEMBL CHEMBL457
ChEBI CHEBI:5296
CCDC/CSD XAPVOA, RAXXOH, RAXXUN
COD 2206229